Literature DB >> 18852401

Procalcitonin-guided antibiotic use vs a standard approach for acute respiratory tract infections in primary care.

Matthias Briel1, Philipp Schuetz, Beat Mueller, Jim Young, Ursula Schild, Charly Nusbaumer, Pierre Périat, Heiner C Bucher, Mirjam Christ-Crain.   

Abstract

BACKGROUND: Acute respiratory tract infections are the most common reason for antibiotic therapy in primary care despite their mainly viral etiology. A laboratory test measuring procalcitonin levels in blood specimens was suggested as a tool to reduce unnecessary prescribing of antibiotics. We consider whether antibiotic therapy guided by procalcitonin reduces the use of antibiotics without increasing the restrictions experienced by patients by more than 1 day.
METHODS: Fifty-three primary care physicians recruited 458 patients, each patient with an acute respiratory tract infection and, in the physician's opinion, in need of antibiotics. Patients were centrally randomized to either a procalcitonin-guided approach to antibiotic therapy or to a standard approach. For patients randomized to procalcitonin-guided therapy, the use of antibiotics was more or less strongly discouraged (procalcitonin level, < or =0.1 or < or =0.25 microg/L, respectively) or recommended (procalcitonin level, >0.25 microg/L). Follow-up data were collected at 7 days by treating physicians and at 14 and 28 days by blinded interviewers.
RESULTS: Adjusted for baseline characteristics, the mean increase at 14 days in days in which activities were restricted was 0.14 with procalcitonin-guided therapy (95% confidence interval [CI], -0.53 to 0.81 days), which met our criterion of an increase in days in which activities were restricted by no more than 1 day. With procalcitonin-guided therapy, the antibiotic prescription rate was 72% lower (95% CI, 66%-78%) than with standard therapy. Both approaches led to a similar proportion of patients reporting symptoms of ongoing or relapsing infection at 28 days (adjusted odds ratio, 1.0 [95% CI, 0.7-1.5]).
CONCLUSIONS: As an adjunct to guidelines, procalcitonin-guided therapy markedly reduces antibiotic use for acute respiratory tract infections in primary care without compromising patient outcome. In practice, this could be achieved with 1 to 2 procalcitonin measurements in patients for whom the physician intends to prescribe antibiotics.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18852401     DOI: 10.1001/archinte.168.18.2000

Source DB:  PubMed          Journal:  Arch Intern Med        ISSN: 0003-9926


  96 in total

1.  Use of procalcitonin (PCT) to guide discontinuation of antibiotic use in an unspecified sepsis is an antimicrobial stewardship program (ASP).

Authors:  Y X Liew; M P Chlebicki; W Lee; L Y Hsu; A L Kwa
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2011-01-29       Impact factor: 3.267

Review 2.  An ESICM systematic review and meta-analysis of procalcitonin-guided antibiotic therapy algorithms in adult critically ill patients.

Authors:  Dimitrios K Matthaiou; Georgia Ntani; Marina Kontogiorgi; Garyfallia Poulakou; Apostolos Armaganidis; George Dimopoulos
Journal:  Intensive Care Med       Date:  2012-04-27       Impact factor: 17.440

Review 3.  Meta-analysis and systematic review of procalcitonin-guided therapy in respiratory tract infections.

Authors:  Hui Li; Yi-Feng Luo; Timothy S Blackwell; Can-Mao Xie
Journal:  Antimicrob Agents Chemother       Date:  2011-09-26       Impact factor: 5.191

4.  Clinical pearls in infectious diseases.

Authors:  Robert Orenstein; Scott C Litin
Journal:  Mayo Clin Proc       Date:  2010-02       Impact factor: 7.616

5.  Comparison of serum procalcitonin in respiratory infections and bloodstream infections.

Authors:  Yanhui Zhu; Yulin Yuan; Huayi Huang
Journal:  Int J Clin Exp Med       Date:  2015-11-15

6.  Diagnostic use of serum procalcitonin levels in pulmonary aspiration syndromes.

Authors:  Ali A El-Solh; Hardik Vora; Paul R Knight; Jahan Porhomayon
Journal:  Crit Care Med       Date:  2011-06       Impact factor: 7.598

Review 7.  Procalcitonin: present and future.

Authors:  H H Liu; J B Guo; Y Geng; L Su
Journal:  Ir J Med Sci       Date:  2015-07-10       Impact factor: 1.568

Review 8.  Procalcitonin in sepsis and systemic inflammation: a harmful biomarker and a therapeutic target.

Authors:  Kenneth L Becker; Richard Snider; Eric S Nylen
Journal:  Br J Pharmacol       Date:  2009-11-27       Impact factor: 8.739

Review 9.  Effect of procalcitonin-guided treatment in patients with infections: a systematic review and meta-analysis.

Authors:  H Tang; T Huang; J Jing; H Shen; W Cui
Journal:  Infection       Date:  2009-10-13       Impact factor: 3.553

10.  New approaches to sepsis: molecular diagnostics and biomarkers.

Authors:  Konrad Reinhart; Michael Bauer; Niels C Riedemann; Christiane S Hartog
Journal:  Clin Microbiol Rev       Date:  2012-10       Impact factor: 26.132

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.